D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

Y. Tsujimoto, L. Finger, J. Yunis, P. Nowell, and C. Croce, Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation, Science, vol.226, issue.4678, pp.1097-1106, 1984.
DOI : 10.1126/science.6093263

Y. Tsujimoto, J. Yunis, L. Onorato-showe, J. Erikson, P. Nowell et al., Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation, Science, vol.224, issue.4656, pp.1403-1409, 1984.
DOI : 10.1126/science.6610211

P. Czabotar, G. Lessene, A. Strasser, and J. Adams, Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy, Nature Reviews Molecular Cell Biology, vol.5, issue.1, pp.49-63, 2014.
DOI : 10.1038/sj.cdd.4402178

A. Delbridge, S. Grabow, A. Strasser, and D. Vaux, Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies, Nature Reviews Cancer, vol.17, issue.2, pp.99-109, 2016.
DOI : 10.1101/gad.1103603

R. Youle and A. Strasser, The BCL-2 protein family: opposing activities that mediate cell death, Nature Reviews Molecular Cell Biology, vol.94, issue.1, pp.47-59, 2008.
DOI : 10.1038/nrm1697

O. Neill, K. Huang, K. Zhang, J. Chen, Y. Luo et al., Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane, Genes & Development, vol.30, issue.8, pp.973-88, 2016.
DOI : 10.1101/gad.276725.115

P. Czabotar, D. Westphal, G. Dewson, S. Ma, C. Hockings et al., Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis, Cell, vol.152, issue.3, pp.519-550, 2013.
DOI : 10.1016/j.cell.2012.12.031

URL : https://doi.org/10.1016/j.cell.2012.12.031

A. Ashkenazi, W. Fairbrother, J. Leverson, and A. Souers, From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors, Nature Reviews Drug Discovery, vol.2, issue.4, pp.273-84, 2017.
DOI : 10.1002/prot.24816

T. Oltersdorf, S. Elmore, A. Shoemaker, R. Armstrong, D. Augeri et al., An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, vol.360, issue.7042, pp.677-81, 2005.
DOI : 10.1016/0014-5793(95)00062-E

W. Wilson, O. Connor, O. Czuczman, M. Lacasce, A. Gerecitano et al., Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity, The Lancet Oncology, vol.11, issue.12, pp.1149-59, 2010.
DOI : 10.1016/S1470-2045(10)70261-8

A. Roberts, J. Seymour, J. Brown, W. Wierda, T. Kipps et al., Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, Journal of Clinical Oncology, vol.30, issue.5, pp.488-96, 2012.
DOI : 10.1200/JCO.2011.34.7898

C. Tse, A. Shoemaker, J. Adickes, M. Anderson, J. Chen et al., ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor, Cancer Research, vol.68, issue.9, pp.3421-3429, 2008.
DOI : 10.1158/0008-5472.CAN-07-5836

URL : http://cancerres.aacrjournals.org/content/canres/68/9/3421.full.pdf

K. Mason, M. Carpinelli, J. Fletcher, J. Collinge, A. Hilton et al., Programmed Anuclear Cell Death Delimits Platelet Life Span, Cell, vol.128, issue.6, pp.1173-86, 2007.
DOI : 10.1016/j.cell.2007.01.037

URL : https://doi.org/10.1016/j.cell.2007.01.037

S. Stilgenbauer, B. Eichhorst, J. Schetelig, S. Coutre, J. Seymour et al., Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, The Lancet Oncology, vol.17, issue.6, pp.768-78, 2016.
DOI : 10.1016/S1470-2045(16)30019-5

J. Porter, A. Payne, B. De-candole, D. Ford, B. Hutchinson et al., Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.1, pp.230-233, 2009.
DOI : 10.1016/j.bmcl.2008.10.113

S. Varadarajan, M. Vogler, M. Butterworth, D. Dinsdale, L. Walensky et al., Evaluation and critical assessment of putative MCL-1 inhibitors, Cell Death & Differentiation, vol.15, issue.11, pp.1475-84, 2013.
DOI : 10.1593/neo.13230

URL : http://www.nature.com/cdd/journal/v20/n11/pdf/cdd201379a.pdf

L. Diguarher, T. Casara, P. Starck, J. Henlin, J. Davidson et al., New indolizine compounds, a process for their preparation and pharmaceutical compositions containing them, 2013.

G. Ferenczy and G. Keseru, Enthalpic Efficiency of Ligand Binding, Journal of Chemical Information and Modeling, vol.50, issue.9, pp.1536-1577, 2010.
DOI : 10.1021/ci100125a

D. Gaizo-moore, V. Schlis, K. Sallan, S. Armstrong, S. Letai et al., BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia, Blood, vol.111, issue.4, pp.2300-2309, 2008.
DOI : 10.1182/blood-2007-06-098012

A. Gottschalk, L. Boise, Z. Oltvai, M. Accavitti, S. Korsmeyer et al., The ability of Bcl-x(L) and Bcl-2 to prevent apoptosis can be differentially regulated, Cell Death Differ, vol.3, pp.113-121, 1996.

D. Gaizo-moore, V. Brown, J. Certo, M. Love, T. Novina et al., Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737, Journal of Clinical Investigation, vol.117, issue.1, pp.112-133, 2007.
DOI : 10.1172/JCI28281DS1

D. Chiron, C. Dousset, C. Brosseau, C. Touzeau, S. Maïga et al., Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-59, 2015.
DOI : 10.18632/oncotarget.3275

URL : http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=3275&path%5B%5D=7896

J. Huang, W. Sanger, T. Greiner, L. Staudt, D. Weisenburger et al., The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile, Blood, vol.99, issue.7, pp.2285-90, 2002.
DOI : 10.1182/blood.V99.7.2285

J. Iqbal, V. Neppalli, G. Wright, B. Dave, D. Horsman et al., Expression Is a Prognostic Marker for the Activated B-Cell???Like Type of Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.24, issue.6, pp.961-969, 2006.
DOI : 10.1200/JCO.2005.03.4264

E. Coustan-smith, A. Kitanaka, C. Pui, L. Mcninch, W. Evans et al., Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia, Blood, vol.87, pp.1140-1146, 1996.

J. Irish, N. Anensen, R. Hovland, J. Skavland, A. Borresen-dale et al., Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53, Blood, vol.109, issue.6, pp.2589-96, 2007.
DOI : 10.1182/blood-2006-02-004234

URL : http://www.bloodjournal.org/content/bloodjournal/109/6/2589.full.pdf

I. Marschitz, I. Tinhofer, A. Hittmair, A. Egle, M. Kos et al., Analysis of Bcl-2 Protein Expression in Chronic Lymphocytic Leukemia, American Journal of Clinical Pathology, vol.55, issue.2, pp.219-248, 2000.
DOI : 10.1038/bjc.1997.60

URL : https://academic.oup.com/ajcp/article-pdf/113/2/219/4983459/ajcpath113-0219.pdf

G. Calin, A. Cimmino, M. Fabbri, M. Ferracin, S. Wojcik et al., MiR-15a and miR-16-1 cluster functions in human leukemia, Proceedings of the National Academy of Sciences, vol.5, issue.13, pp.5166-71, 2008.
DOI : 10.1093/nar/gni178

URL : http://www.pnas.org/content/105/13/5166.full.pdf

A. Cimmino, G. Calin, M. Fabbri, M. Iorio, M. Ferracin et al., miR-15 and miR-16 induce apoptosis by targeting BCL2, Proceedings of the National Academy of Sciences, vol.101, issue.11, pp.13944-13953, 2005.
DOI : 10.1002/cncr.20696

URL : http://www.pnas.org/content/102/39/13944.full.pdf

L. Garraway and P. Janne, Circumventing Cancer Drug Resistance in the Era of Personalized Medicine, Cancer Discovery, vol.2, issue.3, pp.214-240, 2012.
DOI : 10.1158/2159-8290.CD-12-0012

V. Fresquet, M. Rieger, C. Carolis, M. Garcia-barchino, and J. Martinez-climent, Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, issue.26, pp.4111-4120, 2014.
DOI : 10.1182/blood-2014-03-560284

URL : http://www.bloodjournal.org/content/bloodjournal/123/26/4111.full.pdf

S. Tahir, M. Smith, P. Hessler, L. Rapp, K. Idler et al., Potential mechanisms of resistance to venetoclax and strategies to circumvent it, BMC Cancer, vol.15, issue.1, p.399, 2017.
DOI : 10.1016/j.clml.2015.03.006

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-017-3383-5?site=bmccancer.biomedcentral.com

K. Lin, P. Winter, A. Xie, C. Roth, C. Martz et al., Targeting MCL-1/ BCL-XL Forestalls the Acquisition of Resistance to ABT- 199 in, Acute Myeloid Leukemia. Sci Rep, vol.6, p.27696, 2016.

G. Lessene, P. Czabotar, B. Sleebs, K. Zobel, K. Lowes et al., Structure-guided design of a selective BCL-XL inhibitor, Nature Chemical Biology, vol.60, issue.6, pp.390-397, 2013.
DOI : 10.1107/S0907444904019158

J. Leverson, D. Phillips, M. Mitten, E. Boghaert, D. Diaz et al., Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy, Science Translational Medicine, vol.29, issue.279, pp.279-319, 2015.
DOI : 10.1007/978-1-60327-017-5_11

A. Kotschy, Z. Szlavik, J. Murray, J. Davidson, A. Maragno et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models, Nature, vol.318, issue.7626, pp.477-82, 2016.
DOI : 10.1038/318533a0

J. Leverson, H. Zhang, J. Chen, S. Tahir, D. Phillips et al., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death & Disease, vol.15, issue.1, p.1590, 2015.
DOI : 10.1172/JCI39964

URL : http://www.nature.com/cddis/journal/v6/n1/pdf/cddis2014561a.pdf

Z. Nikolovska-coleska, R. Wang, X. Fang, H. Pan, Y. Tomita et al., Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization, Analytical Biochemistry, vol.332, issue.2, pp.261-73, 2004.
DOI : 10.1016/j.ab.2004.05.055

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. Margolin et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.53, issue.7391, pp.603-610, 2012.
DOI : 10.1002/pbc.20697

URL : http://europepmc.org/articles/pmc3320027?pdf=render